Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

Linda Stein Gold(Henry Ford Health System), Kim Papp(University of Toronto), Manish R. Patel(Sarah Cannon), Huzefa Photowala(AbbVie (United States)), Jerry Bagel, Andreas Pinter(Goethe University Frankfurt), Leonidas Drogaris(AbbVie (United States)), Adam Reich(Rzeszów University of Technology), Hwanhee Hong(University of British Columbia), Lev Pavlovsky(Tel Aviv University), Tianshuang Wu(AbbVie (United States)), Vassilis Stakias(AbbVie (United States)), Sven Richter(AbbVie (United States)), Ronald Vender(Dermatrials Research), Ahmed M. Soliman(AbbVie (United States)), Stephen K. Tyring(Center for Clinical Studies)
British Journal of Dermatology
July 20, 2023
10.1093/bjd/ljad252
Cited by 22

Related Papers

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Recommendations for the Management of Herpes Zoster
|Clinical Infectious Diseases|2006|842
Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus
|Acta Dermato Venereologica|2012|579
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
|The Lancet|2015|566